Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
The development of novel agents has transformed the treatment paradigm for multiple myeloma, with MRD negative response now achievable both in newly diagnosed and relapsed disease. Additional technologies including mass spectrometry-based paraprotein analyses, cfDNA, scRNAseq, as well as whole body DWI MRI and novel tracers for imaging are rapidly evolving and may be used to measure MRD in the future. The pace of advances in targeted and immune therapies in multiple myeloma is unprecedented and will assure that these scientific advances translate to clinical trials leading to regulatory approval of novel treatments and continued improvement in patient outcomes.